This article explores the pros and cons of next-generation psychedelics without the trip, including insights from Frederick Barrett, Jason Wallach and David E. Olson as well as representatives from companies like COMPASS Pathways, atai Life Sciences and Eleusis.
Companies FeaturedCOMPASS Pathways
COMPASS Pathways is a publicly listed company (NASDAQ) that is developing psilocybin for treatment-resistant depression (TRD) for which it has completed a successful Phase IIb trial. COMPASS is one of the largest psychedelic companies and has received substantial investment from atai.
atai Life Sciences
atai Life Sciences is one of the biggest companies in the psychedelics field. The company aims to be a platform and has nine subsidiary companies working on everything from psilocybin for depression to DMT administration.
Eleusis is a clinical-stage life sciences company that studies and develops psychedelic drugs for therapeutic use. Since 2013 the company has been researching psychedelics and is now developing ELE-Psilo (psilocybin) for depression that is in Phase I.
Delix Therapeutics is a drug development company focusing on novel psychedelic formulations.
Gilgamesh is a preclinical biotechnology company focused developing new chemical entities in the psychedelic space.
Viridia Life Sciences
Viridia Life Sciences is a subsidiary of ATAI that investigates DMT and the possible administration of it.